Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Short Interest Up 107.4% in June

Posted by Stanley Muller on Jul 2nd, 2026

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Get Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 101,771 shares, a growth of 107.4% from the May 31st total of 49,071 shares. Based on an average daily volume of 954,316 shares, the days-to-cover ratio is presently 0.1 days. Approximately 11.3% of the shares of the company are short sold.

Purple Biotech Trading Down 4.1%

Purple Biotech stock opened at $1.68 on Thursday. The firm has a market cap of $1.56 million, a PE ratio of -0.09 and a beta of 0.68. Purple Biotech has a 12 month low of $1.42 and a 12 month high of $29.00. The stock’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $4.64.

Purple Biotech (NASDAQ:PPBT – Get Free Report) last posted its earnings results on Saturday, May 16th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.29. On average, equities research analysts forecast that Purple Biotech will post -5.31 EPS for the current year.

Hedge Funds Weigh In On Purple Biotech

A hedge fund recently bought a new stake in Purple Biotech stock. SmartHarvest Portfolios LLC acquired a new position in shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 47,454 shares of the company’s stock, valued at approximately $31,000. SmartHarvest Portfolios LLC owned 0.37% of Purple Biotech as of its most recent filing with the Securities & Exchange Commission. 9.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on PPBT shares. HC Wainwright cut their price objective on Purple Biotech from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Weiss Ratings raised Purple Biotech from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 26th. Finally, Zacks Research upgraded Purple Biotech from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Purple Biotech currently has a consensus rating of “Hold” and an average target price of $30.00.

View Our Latest Stock Analysis on Purple Biotech

Purple Biotech Company Profile

(Get Free Report)

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.